Dr Konstantinos Tzelepis

No Image
Dr Konstantinos Tzelepis
Group Leader
The Milner Therapeutics Institute


Presentations at Drug Discovery 2021 After the Storm: Re-connect, Re-invent, Re-imagine

Profile of Dr Konstantinos Tzelepis

The Tzelepis group is focusing on the discovery of novel therapeutic targets and the bench-to-clinic transition of new treatments for aggressive malignancies including acute myeloid leukaemia (AML). Dr Tzelepis’s recent work has led to the development of sophisticated CRISPR screening platforms which formed the basis for his follow-up studies that identified the role of several new cancer vulnerabilities including the RNA methyltransferases METTL3 and METTL1 as well as the splicing kinase SRPK1. Now, his group is investigating how the structures and modifications of the RNA regulate the initiation and maintenance of devastated diseases.


Please login to send a Private Message

Hosted By

The European Laboratory Research & Innovation Group Our Vision : To provide outstanding, leading edge knowledge to the life sciences community on an open access basis
Event Logo Find us on Facebook Follow us on Twitter

Get the App

Get this event information on your mobile by
going to the appstore or google play and search for 'elrig'
Eventflo Home
copyright ELRIG, eventflo.co.uk, Labhoo Ltd 2003-2021